Detalles de la búsqueda
1.
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 8: e2300527, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38603652
2.
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
; 40(19): 2138-2147, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35290101
3.
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Gynecol Oncol
; 121(3): 455-61, 2011 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21414654
4.
Overcoming the Stress of Malpractice Litigation: Solutions to Help Physicians Stay Healthy and Engaged.
Mich Med
; 115(1): 18, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26901997
5.
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
Gynecol Oncol
; 116(3): 323-5, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20044128
6.
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Gynecol Oncol
; 108(1): 90-4, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17949799
Resultados
1 -
6
de 6
1
Próxima >
>>